During the last decade, a host of epigenetic mechanisms were found to contribute to cancer and other human diseases. Several genomic studies have revealed that 20% of malignancies have alterations of the subunits of polymorphic BRG-/BRM-associated factor (BAF) and Polybromo-associated BAF (PBAF) complexes, making them among the most frequently mutated complexes in cancer. Recurrent mutations arise in genes encoding several BAF/ PBAF subunits, including ARID1A, ARID2, PBRM1, SMARCA4, and SMARCB1. These subunits share some degree of conservation with subunits from related adenosine triphosphate (ATP)-dependent chromatin remodeling complexes in model organisms, in which a large body of work provides insight into their roles in cancer. Here, we review the roles of BAF-and PBAF-like complexes in these organisms, and relate these findings to recent discoveries in cancer epigenomics. We review several roles of BAF and PBAF complexes in cancer, including transcriptional regulation, DNA repair, and regulation of chromatin architecture and topology. More recent results highlight the need for new techniques to study these complexes.
B
roadly defined, epigenetic factors contribute to the expression state of the genome by regulating heritable changes in gene expression independently of the DNA sequence. Chromatin-based epigenetic regulation occurs through a wide variety of mechanisms, including physical compaction and exclusion, recruitment of transcription machinery, or covalent modification of DNA and histones. Such features constitute the heritable physicochemical state of the genetic material, and are jointly referred to as the epigenetic landscape. The combinatorial regulation of these features represents the full spectrum of achievable cell-type diversity for the organism. Because epigenetic regulation contributes to cell-type functional specialization, it is essential for multicellular life.
An important component of the epigenetic state is the regulation provided by adenosine triphosphate (ATP)-dependent chromatin remodelers, which use ATP to physically remodel histones and other factors on chromatin. As we review below, genomic studies of primary tumors and cancer cell lines have revealed that ATP-dependent chromatin remodelers are among the most frequently disrupted genes in cancer. Because several important components of ATP-dependent chromatin remodelers are conserved between yeast, flies, and humans ( Fig. 1) , the basic research on chromatin remodeling performed in model organisms is taking on new relevance for disease biology. In many cases, fundamental observations from yeast and flies directly support our understanding of the role of chromatin remodelers in cancer; in other cases, the differences between these organisms and humans highlight important gaps in our knowledge of disease mechanisms.
In this review, we focus on the family of BRG-/BRM-associated factor ([BAF] or mSWI/ SNF) and Polybromo-associated BAF (PBAF) complexes, whose subunits have been identified as major tumor suppressors in several malignancies (Davoli et al. 2013; Shain and Pollack 2013) . Here, we relate the fundamental biology revealed by genetics, structural biology, and microscopy to the fast-moving field of cancer epigenomics. As we discuss below, the mechanisms revealed by fundamental studies inform our understanding of how epigenetic dysfunction contributes to cancer.
SWI/SNF AND RSC IN Saccharomyces cerevisiae
The SWI/SNF Complex ATP-dependent chromatin remodelers were independently discovered in yeast, by screening for mutations that disrupt the ability of yeast to switch mating type (Stern et al. 1984) or activate sucrose fermentation pathways (Carlson et al. 1981; Carlson 1984, 1987) , both in response to extrinsic cues. Later work showed that many of these genes act in concert through a common complex that regulated transcription, termed SWI/SNF to honor both discoveries (Peterson and Herskowitz 1992; Winston and Carlson 1992; Cairns et al. 1994; Peterson et al. 1994) . The observation that histone mutants were able to reverse the phenotypic defects associated with SWI/SNF mutation (Sternberg et al. 1987; Kruger et al. 1995) indicated that regulation of chromatin structure was the central function of the SWI/SNF complex. In vitro, ATP-dependent remodeling activity induces changes of position, phasing, stability, or histone content of nucleosomes, and is well described in other reviews (Becker and Horz 2002; Narlikar et al. 2013) . However, as we discuss below, SWI/SNF-like complexes have rich and biologically diverse regulatory roles in vivo that arise through mechanisms that are not entirely clear.
In yeast, SWI/SNF is a 1.15-MDa protein complex (Smith et al. 2003 ) composed of Swi1, Snf2, Swi3, Snf5, Snf6, along with Swpand actin-related proteins (ARPs) (Fig. 1) . Most subunits of the complex, including the ATPase Snf2, are present as single copies in the complex, whereas several others integrate in multiple copies (two copies of Swi3, Swp82, Snf6, and Snf11, and three copies of Swp29) (Smith et al. 2003) . Many of these subunits are required for the complex's biological activity and, in some cases, its biochemical stability (Estruch and Carlson 1990; Richmond and Peterson 1996) . The complex's direct interaction with nucleosomal DNA is mediated by the catalytic subunit Snf2, whereas other subunits, such as Snf5, do not interact with nucleosomal DNA but instead contact the histone octamer (Dechassa et al. 2008) .
Cells with SWI/SNF subunit mutations have disrupted chromatin structures, and fail to express many genes, leading to diverse phenotypic defects. As a result, several aspects of the complex's biological activity are illustrated by genetic deletion of its subunits.
Failure to activate gene expression affects several downstream processes. As an example, cells lacking the central ATPase Snf2 are viable but have impaired mating-type switching because of the inability to express the HO endonuclease needed for the process. Proper expression of HO depends not only on Snf2, but also Snf1 and Swi3 (Stern et al. 1984) . In addition to the effects on sucrose metabolism, snf2D cells also have impaired sporulation. However, SWI/SNF activity is not uniformly activating. Although Snf2 plays a role in activation of many genes, it also is required for silencing of genes at rDNA and telomeric loci, either by direct or indirect means (Dror and Winston 2004; Manning and Peterson 2014) .
SWI/SNF subunits also have important functions in maintaining proper chromatin- Homology between BAF and PBAF-like remodelers throughout evolution. (A) BAF and PBAF complexes in mammals share several features with Brahma-associated proteins (BAPs) and Polybromo-associated BAP (PBAP) complexes (Drosophila melanogaster), and SWI/SNF and RSC complexes (Saccharomyces cerevisiae), respectively. The similarities and differences between these complexes throughout evolution provide insight into their biological regulation and their roles in cancer. BAF/PBAF subunits labeled in a boldface white font have important roles in malignancy. Time since species divergence was estimated using TimeTree (Hedges et al. 2006) , and plotted as a function of time, millions of years ago (Mya). (B) Summary of BAF and PBAF subunits and alternative names used in the text. In some cases, abbreviated names rather than the official human genome organization (HUGO) symbols are used in the text because of space constraints. modification domains. In a reporter strain that lacks a native transfer RNA (tRNA) insulator element, nucleosomes occupy a region from which they are normally depleted, leading to loss of insulator function (Oki et al. 2004) . In this system, artificial recruitment of Snf5 or Snf6 restores the nucleosome-depleted region over which heterochromatin marks cannot spread, thereby rescuing barrier function. SWI/SNF mutations also cause increased sensitivity to DNA-damaging agents, including hydroxyurea, cisplatin, methyl methanesulfonate, and ultraviolet (UV) light (Birrell et al. 2001; Chai et al. 2005; Xia et al. 2007 ). These defects may arise because SWI/SNF subunits have roles in nucleotide excision repair (Gong et al. 2006 ) and DNA double-strand break (DSB) repair through the homologous recombination (HR) pathway (Chai et al. 2005) . SWI/ SNF defective cells also show increased sensitivity to the topoisomerase II inhibitor daunorubicin (Xia et al. 2007) .
Because transcription, DNA repair, and chromatin modification domains are each influenced by the availability of accessible DNA, disruption of the nucleosome mobilization activity of SWI/SNF has distinct and pleiotropic effects.
The RSC Complex
In budding yeast, STH1 codes for the ATPase subunit of the RSC complex, which also has the capacity to remodel the structure of chromatin. In addition to Sth1, whose ATPase domain is functionally interchangeable with Snf2 (Laurent et al. 1993) , the RSC complex also has Rsc4, Rsc6, Rsc8, Rsc9, Sfh1, and several other dedicated subunits (Fig. 1) . In budding yeast, there are two distinct RSC complexes, containing either of the two paralogs Rsc1 or Rsc2 that arose from gene duplication. Both subunits along with Rsc4 contain bromodomains, which interact with acetylated lysines. RSC complexes are 10-fold more abundant that SWI/SNF (Cairns et al. 1996 (Cairns et al. , 1999 , which may explain why RSC complexes are essential but SWI/SNF is not. Electron microscopic (EM) reconstructions of the yeast RSC complex show a lobed 1.3-MDa structure of similar scale to the SWI/SNF complex (Asturias et al. 2002; Leschziner et al. 2007; Chaban et al. 2008) .
RSC remodels nucleosomes throughout the genome, regulating the positions and densities of histones near the promoters of genes transcribed by RNA polymerase II (Pol II), as well as genes transcribed by Pol III (Parnell et al. 2008; Hartley and Madhani 2009) , and its activity affects the transcription state of both classes of genes.
Rsc2 is required for insulator boundary function at the HMR locus, and its mutation leads to a loss of the nucleosome-depleted region encompassed by the insulator (Dhillon et al. 2009 ). Additionally, loss of Rsc2 impairs HR and nonhomologous end joining (NHEJ), the two DSB-repair pathways, along with repair of DNA damaged by UV light (Chai et al. 2005; Shim et al. 2005; Srivas et al. 2013) . Rsc2 is present at kinetochores and is required for proper sister chromosome cohesion and chromosome segregation (Hsu et al. 2003; Baetz et al. 2004) , as well as maintenance of telomeres (Askree et al. 2004 ). Complexes similar to yeast SWI/SNF were discovered in Drosophila based on their ability to oppose Polycomb repressive activity (Kennison and Tamkun 1988; Tamkun et al. 1992) . The central ATPase of this complex is the gene product of brahma (brm), giving rise to the name BAP complex. The BAP complex is defined as containing OSA and lacking BAP170, SAYP, and POLYBROMO ( Fig. 1) (Mohrmann et al. 2004; Bouazoune and Brehm 2006; Chalkley et al. 2008) .
In flies, the activating Trithorax group genes generally oppose the repressive activity of Polycomb group genes. Misregulation of developmental genes results in aberrant morphologies and ectopic locations of body parts. Proteins encoded by brahma, osa, and moira (mor) are members of the Trithorax group, a set of factors that oppose the repressive activity of Polycombgroup proteins (Kennison and Tamkun 1988; Tamkun et al. 1992; Papoulas et al. 1998; Collins et al. 1999; Crosby et al. 1999; Kal et al. 2000; Simon and Tamkun 2002; Kingston and Tamkun 2014) .
Although Polycomb genes are conserved in animals, plants, and some fungi (Shaver et al. 2010) , unicellular model yeasts lack Polycomb, suggesting that multicellular organisms have greater needs for repressive factors (as well as their regulators) for lineage-specific functions during development. As discussed below, failure to oppose Polycomb repressive activity in mammals plays an important role in malignancy. Nevertheless, despite this important regulatory role (likely present in the last common eukaryotic ancestor), the precise mechanisms of Polycomb opposition remain murky.
The PBAP Complex
Drosophila have a second BRM-containing complex, named PBAP. The subunit compositions of the BAP and PBAP complexes bear similarities to the functional specialization between SWI/SNF and RSC in yeast. PBAP complexes lack OSA and instead contain BAP170, SAYP, and POLYBROMO (Mohrmann et al. 2004; Bouazoune and Brehm 2006; Chalkley et al. 2008) . Interestingly, BAP and PBAP subunits both genetically oppose Polycomb-mediated silencing, without regard to whether they are common to BAP and PBAP, or exclusive to one of the complexes (Kennison and Tamkun 1988; Tamkun et al. 1992; Papoulas et al. 1998; Collins et al. 1999; Crosby et al. 1999; Kal et al. 2000; Simon and Tamkun 2002) . On the other hand, the complexes can also have distinct or even opposing functional roles. For example, PBAP but not BAP is required for germinal stem-cell maintenance . Moreover, BAP and PBAP have opposing roles in Egfr expression in wing development; although BAP positively regulates Egfr expression (Molnar et al. 2006; Terriente-Felix and de Celis 2009) , PBAP instead negatively regulates Egfr (Rendina et al. 2010) . Together, these observations suggest that mutations in different subunits or complexes may result in distinct or even opposing changes to the genomic landscape, a fact that complicates straightforward predictions of their effects.
One clue regarding the distinct functions of BAP and PBAP complexes comes from microscopic examination of polytene chromosomes. Polytene chromosomes arise from successive rounds of replication without cell division, resulting in many copies of aligned condensed sister chromatids (Balbiani 1881) . Visualization of chromatin domains using immunofluorescence shows that BAP and PBAP complexes have both overlapping and mutually exclusive domains. Polycomb domains are largely not found at both the overlapping and mutually exclusive BAP/PBAP domains (Armstrong et al. 2002; Mohrmann et al. 2004; Moshkin et al. 2007 ). This pattern suggests that BAP and PBAP work both cooperatively and independently at distinct sites to oppose Polycomb silencing.
BAF AND PBAF IN MAMMALS BAF Complexes
In mammals, highly polymorphic BAF complexes (Wang et al. 1996a,b) are composed of a single central ATPase, either BRG (SMARCA4) or BRM (SMARCA2), and several BRG-/BRMassociated factors (BAF subunits) (Khavari et al. 1993) . In addition to the subunits homologous to those in Drosophila or yeast, several other subunits appear to be dedicated to vertebrate or mammalian complexes, including SS18/ SS18L1, BCL7A/B/C, BCL11/A/B, and BRD9 (see Fig. 1 ). Scanning force microscopy of BAF complexes isolated from HeLa cells show objects with similar appearances and dimensions as yeast SWI/SNF or RSC (Schnitzler et al. 2001) ; however, BAF subunits are frequently inactivated in long-term cell lines, and so caution is warranted when inferring the complex's characteristics based on immortalized cancer lines.
ChIP-seq studies in many cell types show that BAF complexes bind 20,000 -40,000 sites genome-wide, with broad binding sites sometimes spanning 2-5 kbp, suggesting that more than one complex may operate at a given site (Ho et al. 2009a; Euskirchen et al. 2011) . BAF complexes have many roles in development (Ho and Crabtree 2010) ; the presence of BAF complexes on chromatin correlates with enhancers (Rada-Iglesias et al. 2011) , and its activity regulates a variety of important biological processes ranging from self-renewal and pluripotency in embryonic stem cells (Ho et al. 2009b) , to cardiac development (Lickert et al. 2004) , and neural differentiation (Yoo et al. 2009 ). BAF activity and transcription factor (TF) binding appear to be coupled idiosyncratically, as examples can be found in which TF binding requires BAF activity (Ho et al. 2011; Bao et al. 2015) or, alternatively, in which recruitment of BAF requires existing TF binding (Liu et al. 2001 ). Some of the complexes' subunits are tissue-specific; for example, BAF53B (ACTL6B), BAF45B (DPF1), and SS18L1 (CREST, a Ca 2þ -responsive regulator), are found only in BAF complexes of mature, postmitotic neurons (Olave et al. 2002; Aizawa et al. 2004; Lessard et al. 2007; Staahl et al. 2013) . BAF subunit composition is subject to tight regulation, as miRNA-based repression of BAF53A occurs either before or coincident with the last mitotic division of neurons (Yoo et al. 2009) , and failure to express neural-specific subunits like BAF53B leads to defects in synaptogenesis and dendritic outgrowth Vogel-Ciernia et al. 2013) . BAF subunit composition also contributes substantially to cell reprogramming (Singhal et al. 2010; Yoo et al. 2011) , an instructive effect seemingly incompatible with simple mechanisms of nucleosome mobilization.
Before the modern tumor-sequencing era, the frequent absence of core BAF subunits in immortalized cell lines prompted early speculation that BAF subunits were tumor suppressors (Dunaief et al. 1994) . Screening for BRG mutations revealed widespread defects in a number of different cancer cell lines, and ectopic expression of BRG in these lines often results in altered morphology (Wong et al. 2000) . Moreover, many cell lines down-regulate both BRG and BRM ATPases (Reisman et al. 2002) . In cultured cells, BAF complexes missing the core ATPase fail to bind the tumor suppressor RB1 and suppress E2F1 (Dunaief et al. 1994; Trouche et al. 1997) , although it remains uncertain whether this feature reflects its central role in primary tumors. Moreover, as described below, several specific malignancies are driven entirely by BAF subunit dysfunction. Abundant evidence now shows that BAF complexes act as major tumor suppressors.
PBAF Complexes
PBAF complexes were first discovered by Tjian and colleagues in a search for factors that activated ligand-mediated transcription on nucleosomal templates (Lemon et al. 2001) . PBAF complexes contain PBRM1 and ARID2 but lack ARID1A/B. PBAF complexes also contain BRD7 in place of BRD9 (Kaeser et al. 2008 ), BAF45A (PHF10) instead of BAF45B/C/D (DPF1/3/2), and lack SS18 (see Fig. 1 ) (Middeljans et al. 2012) . EM reconstruction of PBAF complexes from HeLa cells show heterogeneous .1-MDa structures with similarities to RSC from yeast (Leschziner et al. 2005) ; however, because BAF and PBAF complexes are combinatorially assembled, the origin of the observed heterogeneity of these structures remains uncertain. Several subunits share some homology with subunits of the yeast RSC complex, and like RSC, PBAF complexes show significant occupancy at the kinetochores of mitotic chromosomes (Xue et al. 2000) , suggesting an important conserved role in cell division.
PBAF subunits regulate cell differentiation and may be an important regulator of cell-type identity (Bajpai et al. 2010; Xu et al. 2012) . Additionally, a large body of evidence shows that PBAF complexes have important roles in the maintenance of genomic integrity during mitosis, described in more detail below (see section on Nontranscriptional Roles of BAF/PBAF Complexes in Cancer).
BAF AND PBAF SUBUNITS ARE FREQUENTLY DISRUPTED IN CANCER
In mammals, 28 genes have been discovered to date with close sequence homology with the yeast Snf2 ATPase (Fig. 2A) . Despite sharing highly conserved Snf2-like ATPase domains, these ATPases play distinct biological roles and are nearly all functionally nonredundant between the different remodeling families, as reviewed elsewhere (Clapier and Cairns 2009 ).
Based on their distinct biological activities, disruption of each of these remodelers is under a different selection pressure in cancer, resulting in a wide range of mutation frequencies (Fig.  2B ). Across all cancer types, 20% of human malignancies have defects in BAF-related complexes Shain and Pollack 2013) making them among the most frequently mutated chromatin regulatory complexes in malignancy.
In addition to their ATPases BRG and BRM (Khavari et al. 1993) , BAF and PBAF complexes contain a number of noncatalytic subunits that contribute to targeting of the complex to cognate loci, or have other unknown functions. BAF and PBAF complexes collectively contain eight bromodomains (six on PBRM1, one on either BRG or BRM, and one on BRD7 or BRD9), a region homologous with chromodomains (BAF155/170), two PHD finger proteins (BAF45 subunits), a large number of zinc finger and other DNA-binding domains that bind distinct architectural features such as AT-rich sequences or HMG recognition features (Wang et al. 1996a (Wang et al. ,b, 1998 Lessard et al. 2007 ). Some of these subunits are among the most frequently mutated genes in cancer, and highly subunit-specific mutation patterns contribute to different cancer types (Figs. 2C and 3) . Below, we summarize the role of these subunits in the complex, and discuss their contribution to malignancy.
BRG (SMARCA4) Is Mutated in Many Different Malignancies
As defined by the overall number of truncating and high-functional-impact mutations, BRG is the most frequently mutated Snf2-like chromatin remodeling ATPase in cancer (Fig. 2C) . Unlike many other tumor suppressors, hypermethylation and silencing of BRG is reported to be relatively uncommon (Medina et al. 2004; Ramos et al. 2014 ). However, heterozygous and biallelic inactivation of BRG occurs in tumors of the breast (The Cancer Genome Atlas 2012b), lung (The Cancer Genome Atlas 2014c), stomach (The Cancer Genome Atlas 2014a), bladder (The Cancer Genome Atlas 2014b), colon (The Cancer Genome Atlas 2012a), and in several other tumor types and cell lines (Wong et al. 2000) . Disruption of BRG is especially common in small cell ovarian cancer (90% -100%) (Jelinic et al. 2014; Ramos et al. 2014) , cancers of the skin (up to 27%) Li et al. 2015; Shain et al. 2015; The Cancer Genome Atlas 2015) , diffuse large B-cell lymphoma (10%), and non-smallcell lung cancers ( 11%) Rizvi et al. 2015) , in which it has been reported as the fifth most frequently mutated gene (Medina et al. 2004 ). In some specific malignancies, such as certain thoracic sarcomas (Le Loarer et al. 2015) , biallelic inactivation of BRG occurs at elevated frequencies. Although it was initially thought that in most cancers BRG mutations were generally homozygous , it has since been determined that, in many cancer types, a large number of mutations of BRG are heterozygous, with many mutations clustering at conserved motifs of the ATPase domain. Accordingly, CRISPR-Cas9 tiling experiments have shown that the ATPase domain contains the most functionally important domain of BRG (Shi et al. 2015) .
The ATPase domain of Snf2-like remodelers is composed of two conserved subdomains. The amino-terminal ATPase subdomain of BRG contains several residues highly conserved within the SF2 helicase superfamily (Jankowsky and Fairman 2007; Fairman-Williams et al. 2010) . Based on crystal structures of homologous Snf2-like proteins (Durr et al. 2005; Thoma et al. 2005; Wollmann et al. 2011) , many of these residues are predicted to contact ATP (Walker et al. 1982) or communicate the strain of ATP binding and hydrolysis to the site of DNA binding to exert mechanical force (Banroques et al. 2008) , and are frequently mutated in a number of malignancies (Figs. 3 and 4) . Some effects of these mutations have been characterized. For example, K785R and T910M, respectively, observed in melanoma ; The Cancer Genome Atlas 2015), medulloblastoma , and several cancer cell lines, have severely reduced ATPase activity, leading to anaphase bridges and failure of topoisomerase IIa to bind DNA (Dykhuizen et al. 2013) (discussed in greater detail below). Adjacent residues are mutated in a number of different cancer types, suggesting that functional inactivation contributes to diverse malignancies. In other ATP-dependent remodelers, dominantnegative mutations result in phenotypes distinct from subunit deletion (Corona et al. 2004; Skene et al. 2014) , suggesting that the particular mechanisms of inactivation may lead to different downstream effects.
Although the details remain murky, the carboxy-terminal subdomain of Snf2-like ATPases appears to cooperate with the amino-terminal subdomain to exert large-scale motions needed to translocate along DNA (Durr et al. 2005) but may also carry out some other uncharacterized activity. In the carboxy-terminal ATPase subdomain of BRG, R1192 is recurrently mutated in cancer of the stomach, liver, lung, melanoma, esophagus, and breast, as well as in gliomas (Figs. 3 and 4) . Moreover, the homologous position is also mutated in BTAF1, CHD1, and ATRX in several different malignancies, suggesting this well-conserved position may be an Achilles' heel of Snf2-like remodelers. Other nearby mutations at conserved residues in Motif V of the carboxy-terminal subdomain severely compromise ATPase activity in the yeast SWI/SNF complex (Richmond and Peterson 1996; Smith and Peterson 2005) . Although it is clear that commonly observed point mutations disrupt or completely abolish ATPase activity, a complete accounting of the downstream effects of these mutations in malignancy has not yet been performed. BRM, the paralog of BRG that is not a subunit of the PBAF complex, also shows similar clustering of mutations at the amino-and carboxy-terminal helicase-like subdomains, but is much less frequently mutated in cancers (Figs. 3  and 4) . Interestingly, several in-frame deletions in the QLQ domain of BRM have been observed in primary tumors and several cancer cell lines (Reinhold et al. 2012) . BRM and homologs are regulators of splicing (Batsche et al. 2006; Tyagi et al. 2009; Waldholm et al. 2011; Patrick et al. 2015) ; however, the effects of its mutation on alternative splicing remain unknown.
ARID1A in Uterine, Colorectal, Stomach, Bladder, and Other Cancers By far the most frequently disrupted BAF subunit is ARID1A (BAF250A; Fig. 2B ). Large regions of both ARID1A and its paralog ARID1B are low-complexity sequences with unknown function. ARID1A and ARID1B both contain an ARID DNA-binding domain as well as a homologous domain of unknown function (currently designated DUF3518 in Pfam; Fig. 4) . Although the function of this carboxy-terminal domain has not yet been described, it has been speculated to have ubiquitin ligase activity (Li et al. 2010) .
Among the earliest reports of the complex's tumor-suppressor role was the discovery that 50% of ovarian clear cell carcinomas and endometriosis-associated ovarian carcinomas contain inactivating ARID1A mutations (Jones et al. 2010; Wiegand et al. 2010 ). Mutations of ARID1A have since been observed at high frequency in a number of studies, including uterine (Continued) (Right panel) Mechanisms leading to altered BAF/PBAF subunit expression in cancer may also include mutations in enhancers, loss of insulated neighborhoods leading to spreading of heterochromatin over BAF/PBAF genes, enhancer hijacking, and antisense silencing. (B) Heat map of the frequency of subunit alterations across cancer types (frequency includes all nonsilent mutations, biallelic deletions, and gene fusions). Mutation frequencies for malignant rhabdoid tumor (MRT) and synovial sarcoma are inferred from available cytogenetic and mutation data, as described by works cited in the main text. All other data obtained from studies cited in the main text. PCNSL, Primary central nervous system lymphoma; DLBCL, diffuse large B-cell lymphoma; AML, acute myeloid leukemia. endometrial carcinoma (34%) (Kandoth et al. 2013) , colorectal cancers (10%) (The Cancer Genome Atlas 2012a), as well as cancers of the bladder (29%) (Gui et al. 2011) , stomach (34%) (Wang et al. 2011a , cholangiocarcinomas (27%) (Jiao et al. 2013) , neuroblastomas (11%) (Sausen et al. 2013) , and pancreas ( 5%) (Biankin et al. 2012 ). These recurrent loss-of-function mutations make ARID1A the premier tumorsuppressor subunit of the BAF complex; however, very little is known about the mechanisms of how this subunit contributes to malignancy.
Mutations of ARID1A are most frequently truncating mutations (frameshifts and nonsense mutations (Figs. 2C and 4) , which may be degraded by nonsense-mediated decay. Although the ARID domain in mice is critical for the function of the protein, mutations in human cancer are not especially localized to the ARID domain; indeed no missense mutations expected to be of high functional impact have currently been reported in the ARID domain (Fig. 4) . The few missense mutations present are generally predicted to have low or medium functional impact and are distributed uniformly over the gene. The hotspots of truncating mutations that occur are explained in part by frequent ARID1A mutations arising in tumors with mutated DNA polymerase 1 (POLE). As a result of failed leading-strand proofreading during replication, POLE-mutated tumors often have huge numbers of C.T transitions, many of which convert arginine codons (CGA) to stop codons (TGA) (Alexandrov et al. 2013) . Biallelic inactivation of ARID1A does occur, but in many cases ( particularly in gastric and endometrial cancer) mutations occur in only a single allele (Kandoth et al. 2013) . However, hypermethylation of the ARID1A promoter has been observed in many breast cancers; hence, epigenetic silencing mechanisms are also common (Zhang et al. 2013) .
In ovarian cancer, mutation of ARID1A frequently co-occurs with activating mutations of phosphatidylinositol 3-kinase (PI3K). Interestingly, BRG binds the PI3K substrate PIP 2 ( phosphatidylinositol 4,5-bisphosphate), a phospholipid with several roles in signaling and a regulator of actin-related proteins. Binding of PIP 2 by Brg regulates association of the complex with actin (Rando et al. 2002) ; therefore, activating mutations of PI3K may deplete PIP 2 , leading to altered BAF localization or function . Mice with ARID1A/PI3K double mutations, but not mice with only a single ARID1A or PI3K mutation, develop ovarian tumors with features similar to ovarian clear cell carcinoma (Chandler et al. 2015) , suggesting the effects of PIP 2 may be mediated through ARID1A-containing complexes and providing new insight into the cooperation of these two genes in cancer.
ARID1B is mutated in several malignancies and, like ARID1A, these mutations are also mostly truncating (Fig. 4) . However, ARID1B mutations are not as frequent as those of ARID1A (Fig. 2C) . This discrepancy may reflect important functional differences between these two genes, or may instead reflect ARID1B expression in fewer cell types. Interestingly, ARID1B has been identified as one of the most important genes involved in neurodevelopmental disorders (Santen et al. 2012; Tsurusaki et al. 2012; Deciphering Developmental Disorders Study 2015) , further illustrating the relevance of combinatorial subunit assembly of BAF complexes to development and human diseases.
PBRM1 in Clear Cell Renal Carcinoma
PBRM1 (BAF180, Polybromo) is named for the presence of six bromodomains in the protein, and is a defining subunit of the PBAF complex. In renal clear cell carcinoma (ccRCC), mutation or loss of PBRM1 occurs in 41% of cases (Varela et al. 2011) , making it the second-most frequently mutated gene in ccRCC. Like ARID1A in other cancers, the majority of mutations of PBRM1 in ccRCC are truncating mutations (Figs. 2C and 4) , which may not result in protein expression because of nonsense-mediated decay. However, many ccRCC cases have biallelic inactivation of PBRM1, through loss of one allele via focal/chromosomal deletion at chromosome arm 3p, and an inactivating mutation on the remaining allele. Furthermore, hypermethylation of the PBRM1 promoter is generally absent in ccRCC (Ibragimova et al. 2013) , indicating that inactivation occurs primarily through mutation or deletion. Some tumors do contain missense mutations, and although their functional impacts remain uncertain, their presence suggests a degree of nonredundancy between these domains. Although most bromodomains bind acetylated lysines from histones, the role of PBRM1's bromodomains toward targeting of PBAF complexes remains uncertain.
In ccRCC, PBRM1 inactivation frequently coincides with mutation of the VHL (von Hippel -Lindau) tumor suppressor. Because of their close proximity on chromosome arm 3p, focal and chromosome arm-level deletions frequently affect both of these genes simultaneously. However, the striking frequency of inactivating point mutations of PBRM1 alongside VHL and BAP1 mutations suggests that joint inactivation of these genes may potentiate the oncogenic nature of these defects (Gerlinger et al. 2014) .
Like PBRM1, ARID2 (BAF200) encodes another subunit dedicated to PBAF complexes. ARID2 is not a homolog of ARID1A/B, but is instead mutually exclusive with ARID1A/B, although the shared presence of an AT-rich interaction domain (ARID) in these three subunits suggests some common structural similarities. ARID2 is frequently mutated in other malignancies but is apparently not targeted in ccRCC as frequently as PBRM1, suggesting that PBRM1 has an important and distinct functional role as a member of the PBAF complex in kidney cells. ARID2 has been reported to contribute to repression , and is frequently mutated in melanoma Ding et al. 2014; Lee et al. 2015) , non-smallcell lung cancer (Manceau et al. 2013) , as well as in 18% of hepatitis-associated hepatocellular carcinomas . Moreover, the discovery of frequent joint inactivation of PBRM1, ARID2, and BAP1 in biliary-phenotype-displaying subtype of hepatic carcinomas (Fujimoto et al. 2015) suggests that in some contexts they may contribute to malignancy in a cooperative manner.
SMARCB1 in Malignant Rhabdoid Tumors
Perhaps the best-characterized example of a tumor-suppressor role for ATP-dependent chromatin remodeling comes from malignant rhabdoid tumors (MRTs). MRTs are rare but highly lethal childhood cancers that are caused by biallelic inactivation of SMARCB1 (BAF47, SNF5, or INI1), which occurs in nearly all cases (Versteege et al. 1998; Roberts et al. 2000) . The classic loss of heterozygosity observed for SMARCB1 leads to aberrant activation of Hedgehog-Gli and Wnt/b-catenin pathways (Jagani et al. 2010; Mora-Blanco et al. 2014) , and importantly, impairs the ability of BAF/PBAF complexes to regulate the placement and function of Polycomb repressive complexes. As a result of failure to oppose Polycomb, the repressive mark H3K27me3 accumulates at the tumor suppressor p16/INK4A (CDKN2A) locus . The impaired opposition to Polycomb repression plays an important role in cancer, reminiscent of BAP/PBAP complexes throughout development in flies (Tamkun et al. 1992) .
MRTs have remarkably stable diploid genomes except for deletions and mutations at chromosome 22q, where SMARCB1 is located (McKenna et al. 2008; McKenna and Roberts 2009; Lee et al. 2012 ). Exome sequencing also shows that these tumors have among the lowest mutational loads of any human tumor sequenced to date (Lawrence et al. 2014) . Finally, ectopic expression of SMARCB1 reverses Polycomb silencing at the tumor suppressor p16/ INK4A locus, leading to cellular senescence (Oruetxebarria et al. 2004; Kia et al. 2008) , indicating that these tumors are driven exclusively by epigenetic regulation (except for the original genetic inactivation of SMARCB1). In addition to MRTs, SMARCB1 appears to play a role in a number of cancers and other neoplastic disorders, including prostate cancer, epithelioid sarcomas, familial schwannomatosis, and renal medullary carcinomas (Roberts and Biegel 2009; Prensner et al. 2013) . Biallelic inactivation of SMARCB1 has also been reported in 7% -10% of Ewing sarcomas (Jahromi et al. 2012) .
In mouse models, conditional deletion of SMARCB1 leads to T-cell lymphomas with short latency and 100% penetrance (Wang et al. 2011b) , suggesting that SMARCB1 inactivation can cause fast transformation alone without other genetic changes, as observed in MRTs. Interestingly, rhabdoid tumors are not seen in mice with SMARCB1 inactivation, attesting to the tissue-specific and species-specific function of the complexes. Importantly, the pathogenesis of most human malignancies with BAF/PBAF mutations may be different from that of MRTs. With the exception of some noteworthy examples described below, the majority of cancers bearing BAF/PBAF subunit mutations are found in older age groups, in which tumors have long latencies, are highly mutated, and are genomically unstable. Thus, the low mutation rates observed in MRTs may be because of the extremely short latency between biallelic inactivation and transformation, which may not allow accumulation of mutations resulting from impairment of the complex's other functions.
SS18 in Synovial Sarcoma
Synovial sarcoma is an aggressive, poorly differentiated, stem-cell-like soft-tissue malignancy that typically arises in the extremities of young adults. The hallmark of synovial sarcoma is a highly characteristic translocation of chromosomes 18 and X, which fuses the dedicated BAF subunit SS18 (Middeljans et al. 2012) to the SSX fusion partner on the X chromosome (Crew et al. 1995; Naka et al. 2010 ). This fusion occurs in nearly all cases and in some cases is the only known cytogenetic abnormality. Despite the continued existence of the remaining wildtype SS18 allele and unaltered BAF47 alleles, the SS18 -SSX fusion is preferentially assembled into the BAF complex concomitant with complete loss of BAF47 from the complex. BAF complexes containing the SS18 -SSX fusion are retargeted to oncogenic loci such as SOX2 and PAX6, where removal of the repressive histone mark H3K27me3 results in transformation .
Forced overexpression of wild-type SS18, or shRNA-mediated knockdown of the SS18 -SSX fusion, is sufficient to reverse oncogenic BAF subunit composition. Reversion leads to increased levels of H3K27me3 at SOX2 and other oncogenic loci, and loss of proliferation , indicating that transformation is maintained through epigenetic mechanisms. The reversible and remarkably specific pathogenesis of synovial sarcoma suggests that this tumor may be an attractive candidate for development of therapeutics.
A number of similarities exist between synovial sarcoma and MRTs. They are both childhood malignancies driven by a defining alteration of a single BAF subunit, and senescence can be achieved by repair of the affected subunit. Moreover, SMARCB1 activity is abolished in both cancers, albeit through different mechanisms. However, in contrast to MRTs, which transform by failing to oppose Polycomb activity at p16/INK4A, the genetic dominance of the SS18 -SSX fusion in synovial sarcoma arises from its preferential assembly into BAF complexes, and its apparent ability to retarget the complex and oppose Polycomb at oncogenic loci .
BAF53A and the Role of Nuclear Actin/ARPs BAF53A (ACTL6A) is an ARP and a subunit of BAF/PBAF complexes that is rarely mutated in cancer. Instead, BAF53A frequently undergoes amplification in squamous cell malignancies from many different tissues of origin. BAF53A is required for maintenance of hematopoietic stem cell identity (Krasteva et al. 2012) , and also maintains a progenitor state in epidermal cells by repressing KLF4, an activator of differentiation (Bao et al. 2013) . Recent work has also shown that BAF53A is a target of miR-206, a microRNA missing in rhabdomyosarcomas (RMS). The resulting up-regulation of BAF53A in RMS cells contributes to the failure of myogenic cells to properly differentiate (Taulli et al. 2014) , whereas its silencing inhibits proliferation of RMS cells, suggesting that BAF53A promotes proliferation and interferes with differentiation. Therefore, it is appealing to speculate that BAF53A may generally have oncogenic or mitogenic role in many cell types, perhaps based on interaction with the BRG/BRM helicase-SANT-associated (HSA) domain Rando et al. 2002; Szerlong et al. 2008) . Ablation of the HSA domain from Sth1, the ATPase of RSC in yeast, causes the specific loss of ARPs from the complex, and a reduction in the activity of the ATPase.
ARPs are genetically essential subunits of SWI/SNF-like remodelers (Shen et al. 2003; Wu et al. 2007) , and the interaction of actin and ARPs with the HSA domain from Snf2-like ATPases has long been thought to regulate their activity. Although complexes reconstituted without actin or ARPs can achieve remodeling activity comparable to intact complexes in vitro (Phelan et al. 1999) , BAF53A/B is required for BAF function in vivo. The crystal structure of the Snf2 HSA domain with Arp7 and Arp9 shows that actin filament formation is unlikely because of the incompatible position adopted by the ARPs (Schubert et al. 2013) . Thus, rather than binding filamentous actin, the ARPs in the complex may instead modulate ATPase activity or the coupling of ATP hydrolysis to remodeling activity.
Important structural differences exist between the yeast complexes and human complexes . In yeast, both the SWI/ SNF and RSC complexes contain Arp7 and Arp9 as obligate heterodimers (Szerlong et al. 2003 ), but lack actin itself (Cairns et al. 1998; Peterson et al. 1998) . In contrast, BAF and PBAF complexes contain BAF53A/B and actin . Therefore, it remains unclear whether the structures from yeast also apply directly to the mammalian complexes. As a result, it remains unknown how excess BAF53A may affect the activity of BAF and PBAF complexes.
NONTRANSCRIPTIONAL ROLES OF BAF/PBAF COMPLEXES IN CANCER Involvement in DNA Repair and Chromosome Stability
In addition to their well-established roles as epigenetic regulators described above, BAF/PBAF complexes have several nontranscriptional roles that also contribute to malignancy. One nontranscriptional role in cancer is found in DNArepair pathways. Various mechanisms have been proposed for recruitment of BAF/PBAF complexes to sites of DNA damage, including ATM-/ATR-dependent phosphorylation of BAF170 (Peng et al. 2009) , and a direct interaction between g-H2A.X and the BRG bromodomain (Lee et al. 2010 ). In addition, evidence now points to roles for BAF and PBAF in both NHEJ and HR pathways (Ogiwara et al. 2011; Watanabe et al. 2014; Brownlee et al. 2015; Qi et al. 2015) . Therefore, in humans, BAF and PBAF complexes may help protect genomic integrity similar to the INO80 complex in budding yeast (Gerhold et al. 2015) , which interestingly is not frequently mutated in cancer.
In addition to well-established pathways of DNA repair, PBAF complexes have other important roles for maintaining genomic stability. PBRM1 plays a critical role in sister chromatid cohesion, in which misregulation leads to genome instability, anaphase bridges, and aneuploidy (Brownlee et al. 2014) . PBRM1 also plays a role in repriming stalled replication forks similar to yeast RSC complexes (Askree et al. 2004) . Stalled replication forks are common sites of DNA damage, providing another important mechanism for ensuring genome integrity (Niimi et al. 2012) . Recently, roles for PBAF but not BAF have been identified in DNA-damageinduced transcriptional repression that involves PRC1/2 subunits (Kakarougkas et al. 2014) , and ubiquitination of PCNA following DNA damage (Niimi et al. 2015) .
BAF and PBAF subunits occupy regions that are critical for chromosome organization, such as the binding sites of CTCF (CCCTC-binding factor), cohesins, lamin, and replication origins (Euskirchen et al. 2011) . In addition to the loop anchor sites formed by CTCF and cohesins, which appear to be master regulators of topological domains in stem cells and cancer cell lines (Kagey et al. 2010; Dixon et al. 2012; Yan et al. 2013; Dowen et al. 2014; Ji et al. 2015) , several other chromatin organizational elements have been identified in eukaryotes, such as tRNA genes (Kirkland et al. 2013) , repetitive elements (Lunyak et al. 2007 ), transposons (Lippman et al. 2004) , and PRC1-binding sites (Bantignies et al. 2011; Schoenfelder et al. 2015; Wani et al. 2016) . Chromatin architectural sites are often subject to epigenetic regulation (Bell and Felsenfeld 2000; Wang et al. 2012 ) and show significant BAF and PBAF enrichment (Euskirchen et al. 2011) , suggesting that BAF and PBAF may play important roles in regulating overall chromatin architecture.
Synergy between BAF and Topoisomerase Function
Topoisomerases require nucleosome-free DNA (Sperling et al. 2011) , and mutants of BRG that impair ATPase activity induce loss of topoisomerase IIa (TOP2A) binding to DNA, leading to topological defects, anaphase bridges, and partial arrest at the relatively uncharacterized decatenation checkpoint (Dykhuizen et al. 2013) . Lung cancer cell lines with BRG mutations show increased sensitivity to topoisomerase II inhibitors when EZH2 is also inhibited (Fillmore et al. 2015) , suggesting interplay between BAF, TOP2A, and PRC2 in the maintenance of chromatin topology. The importance of BAF's activity toward TOP2A function was recently underlined by the observation that mutations in BAF subunits predict responses to treatment with TOP2A inhibitors Wijdeven et al. 2015) . Importantly, the mechanism of opposition to EZH2 consists of more than opposing its methyltransferase activity (Kim et al. 2015) , and may underlie an aspect of BAF's tumor-suppressor function with significant clinical importance.
TARGETING TUMORS WITH BAF/PBAF DEFICIENCIES
Recent reports suggest new approaches for targeting tumors with altered BAF/PBAF complexes based on synthetic lethality. In several tumor types, inactivation of one BAF/PBAF subunit induces dependency on the continued expression of that subunit's paralog. For example, tumors with BRG mutations frequently depend on the expression of BRM (Aguirre et al. 2014; Wilson et al. 2014) , whereas tumors with ARID1A mutations often depend on ARID1B . Targeting these genetic dependencies represents a novel strategy to attack these tumors. Additionally, loss-offunction of BAF/PBAF subunits may lead to increased Polycomb activity; therefore, inhibition of Polycomb silencing may be beneficial for patients with tumors bearing BAF/PBAF deficiencies. However, the effectiveness of these approaches may depend greatly on the downstream consequences of BAF/PBAF dysfunction within each cell type. For example, PRC2 inhibition may be more beneficial for MRTs than for synovial sarcoma, based on the molecular mechanisms of transformation described above, illustrating the continuing need to examine the epigenetic mechanisms within each tumor type.
PERSPECTIVE AND CLOSING REMARKS
Although abundant evidence indicates that BAF and PBAF defects contribute to malignancy by altering the epigenetic landscape to regulate transcription, many lines of evidence indicate that these defects have pleiotropic effects, because complexes participate in a number of other important chromatin regulatory processes. In addition to their roles in regulating transcrip- Figure 5 . The effects of BAF and PBAF dysfunction in cancer. Dysfunctional BAF/PBAF complexes have been shown to deregulate Polycomb silencing of key tumor suppressors and oncogenes. In model systems, disruption of BAF-and PBAF-like complexes also affects DNA accessibility for transcription and other regulatory factors, and impacts splicing patterns. Given the conserved regulatory roles for BAF-and PBAF-like remodelers in DNA repair, maintenance of chromatin topology and 3D architecture, we anticipate that whole-genome sequencing and new techniques to examine 3D-chromatin architecture may reveal new roles for the complex in addition to its well-defined role as a transcriptional regulator. tion, a body of work from cancer cell lines and model organisms indicates that BAF-and PBAF-like complexes contribute to several other processes, ranging from DNA recombination and repair to maintenance of 3D chromatin architecture and topology (Fig. 5) .
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Nontranscriptional roles Transcriptional effects
Their numerous roles underscore the fact that the epigenetic state is more than simply a regulatory framework for transcription, but instead represents the sum physicochemical state of the genetic material, which impacts a large number of processes. As a result, the fundamental role of any given BAF and PBAF alteration in cancer is likely to be unique to each cancer type, and may reflect the idiosyncratic processes that drive each malignancy (whether oncogene addiction, autocrine signaling, mutagen exposure, chromosomal instability, etc.). Whole-genome sequencing and various new techniques to examine 3D-chromatin architecture may offer substantial insight into the full breadth of the effects of BAF and PBAF dysfunction, and reveal their diverse contributions toward oncogenesis and tumor biology.
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